A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
Phase 1
33
about 9 months
18–85
3 sites in FL, TX
About this study
Researchers are testing how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The trial will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lepodisiran
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: PK: Maximum Concentration (Cmax) of Lepodisiran, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Lepodisiran
Gastroenterology